207 related articles for article (PubMed ID: 11459208)
61. Experience with ambulatory high-dose methotrexate administration as CNS prophylaxis in patients with non-Hodgkin lymphoma.
Pampín R; Labeaga Y; Rodríguez B; Fernández B; Fernández R; Carbajales M
J Oncol Pharm Pract; 2020 Apr; 26(3):549-555. PubMed ID: 31156052
[TBL] [Abstract][Full Text] [Related]
62. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens.
Villalba L; Hicks JE; Adams EM; Sherman JB; Gourley MF; Leff RL; Thornton BC; Burgess SH; Plotz PH; Miller FW
Arthritis Rheum; 1998 Mar; 41(3):392-9. PubMed ID: 9506565
[TBL] [Abstract][Full Text] [Related]
63. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
64. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
65. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature.
Perez-Verdia A; Angulo F; Hardwicke FL; Nugent KM
Pharmacotherapy; 2005 Sep; 25(9):1271-6. PubMed ID: 16164401
[TBL] [Abstract][Full Text] [Related]
66. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS.
Jacomet C; Girard PM; Lebrette MG; Farese VL; Monfort L; Rozenbaum W
AIDS; 1997 Nov; 11(14):1725-30. PubMed ID: 9386807
[TBL] [Abstract][Full Text] [Related]
67. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
68. Understanding and managing methotrexate nephrotoxicity.
Widemann BC; Adamson PC
Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
[TBL] [Abstract][Full Text] [Related]
69. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
70. Failure of leucovorin rescue to prevent reactivation of a solar burn after high dose methotrexate.
Corder MP; Stone WH
Cancer; 1976 Apr; 37(4):1660-2. PubMed ID: 1083286
[TBL] [Abstract][Full Text] [Related]
71. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
72. [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure].
von Poblozki A; Dempke W; Schmoll HJ
Med Klin (Munich); 2000 Aug; 95(8):457-60. PubMed ID: 10985069
[TBL] [Abstract][Full Text] [Related]
73. Pancytopenia, mucositis, and hepatotoxicity after intralesional methotrexate injection in a patient treated with peritoneal dialysis.
Flynn KN; Johnson MS; Brink WC; Smith DL
Am J Health Syst Pharm; 2012 Apr; 69(7):578-82. PubMed ID: 22441788
[TBL] [Abstract][Full Text] [Related]
74. [Leucovorin rescue after continuing infusion of high dose methotrexate].
Yang LH; Lu XT; Gu J; Hua Y; Zhao WH
Zhonghua Er Ke Za Zhi; 2005 May; 43(5):393-4. PubMed ID: 15924763
[No Abstract] [Full Text] [Related]
75. Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice.
Borsi JD; Sagen E; Romslo I; Moe PJ
Pediatr Hematol Oncol; 1990; 7(4):347-63. PubMed ID: 2268535
[TBL] [Abstract][Full Text] [Related]
76. [High-dose methotrexate and cerebral neurotoxicity. Apropos of a case of arachnoiditis].
Brain E; Alexandre J; Minozzi C; Misset JL
Presse Med; 1997 Mar; 26(6):265-8. PubMed ID: 9122123
[TBL] [Abstract][Full Text] [Related]
77. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
[TBL] [Abstract][Full Text] [Related]
78. Successful high-dose methotrexate chemotherapy in a patient with acute lymphocytic leukemia who developed acute renal failure during the initial treatment.
Isoda T; Ito S; Kajiwara M; Nagasawa M
Pediatr Int; 2007 Dec; 49(6):1018-9. PubMed ID: 18045317
[TBL] [Abstract][Full Text] [Related]
79. Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer.
Monjanel-Mouterde S; Lejeune C; Ciccolini J; Merite N; Hadjaj D; Bonnier P; Piana P; Durand A
J Clin Pharm Ther; 2002 Jun; 27(3):189-95. PubMed ID: 12081632
[TBL] [Abstract][Full Text] [Related]
80. Thymidine rescue of high-dose methotrexate in humans.
Howell SB; Ensminger WD; Krishan A; Frei E
Cancer Res; 1978 Feb; 38(2):325-30. PubMed ID: 637906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
